[18F]-DCFPyL

October 6, 2020October 6, 2020

Lantheus Seeks FDA Approval of PyL Prostate Cancer Imaging Agent

News

Lantheus Holdings has submitted an application to the U.S. Food and Drug Administration (FDA) seeking approval of PyL, an investigational imaging agent used to locate prostate cancer lesions. The new ... Read more

July 25, 2019

PyL Imaging Agent Ably Detects Lesions Outside the Prostate, Phase 2/3 Trial Shows

News

PyL, a new imaging agent for positron emission topography (PET) scans, can accurately detect prostate cancer lesions outside the prostate, whether in nearby lymph nodes or in distant locations, clinical ... Read more

December 6, 2018

New Imaging Agent Better at Detecting Signs of Prostate Cancer Recurrence, Study Reports

News

A new imaging agent for use in positron emission tomography (PET) is better than conventional imaging at detecting cancer location and spread in prostate cancer patients suspected of cancer recurrence, ... Read more